Introduction
Great advances have been made in the treatment of patients with acute leukemia over the past two decades owing to the introduction of intensive combination chemotherapy and hematopoietic stem cell transplantation (HSCT). 1 However, the management of adult patients with acute lymphoblastic leukemia (ALL) remains difficult. Although 70-80% of these leukemias achieve complete remission (CR) after intensive chemotherapy, the survival rate at 5 years does not exceed 40% despite various treatments. 2, 3 We are urged by necessity for a novel therapeutic strategy to improve the disease prognosis.
A variety of cytokines, including colony-stimulating factors or interleukins, have been demonstrated to, at least in part, regulate the survival, growth, differentiation and apoptosis of leukemia cells in vitro and in vivo. 4, 5 Cytokines bind to their respective receptors on the cell surface to exert their effect. 5 However, little is known about the expression of cytokine receptors on cells from ALL, and their clinical relevance. 6, 7 Investigations into the cytokine/cytokine receptor system in ALL might provide us clues that lead to develop a new therapeutic approach.
In the present study, we extensively investigated the quantitative expression of cytokine receptors (IL-2R, IL-3R, IL-4R, IL-5R, IL-6R, IL-7R, granulocyte-macrophage colony-stimulating factor R (GM-CSFR), G-CSFR, c-fms, c-mpl, c-kit and FLT3) on cells from a large population of adult ALL patients using flow cytometry and assessed their prevalence and clinical significance.
Materials and methods
Diagnostic samples from 211 Japanese patients (older than 15 years) with newly diagnosed untreated ALL were consecutively collected and studied at the Second Department of Internal Medicine at Mie University School of Medicine during the period from 1987 to 2000. Patients were from two large hospitals in the Osaka or Hiroshima Prefecture, from Mie University Hospital and its related hospitals in the Mie Prefecture, and from Fukui Medical College Hospital in the Fukui Prefecture. All patients gave their informed consent for the procedure involved. The diagnosis and classification of ALL were made according to the French-American-British (FAB) criteria and the immunophenotype. Of the 211 ALL cases, 164 cases were classified as B-lineage ALL and 47 were as T-lineage ALL. All of the B-lineage ALL cases were diagnosed as B-cell precursor ALL, and they were composed of 27 CD19 þ CD10 À ALL cases and 137 CD19 þ CD10 þ ALL (common ALL) cases. Fresh mononuclear cells (MNC) were separated from either heparinized bone marrow (BM) or peripheral blood (PB) samples by Ficoll-Hypaque centrifugation and were immediately processed. In some cases, stocked samples, which had been isolated and frozen at À1961C in Rosewell Park Memorial Institute medium1640 with 20% fetal calf serum (FCS; Gibco Lab, Charling Falls, OH, USA) and 10% dimethylsulfoxide were also used as needed after Ficoll-Hypaque recentrifugation. The viability of the cells was confirmed using Trypan blue staining and samples with lower viability were excluded.
Surface marker analysis
Surface marker analysis was performed by a standard indirect immunofluorescence. Before analysis, MNC were treated with 5% heat-aggregated human AB serum to block binding owing to receptors for IgG Fc potion (FcgR). MAbs used were Leu1 (CD5), Leu2 (CD8), Leu3a (CD4), Leu4 (CD3), Leu12 (CD19), Leu16 (CD20) and HPCA1 (CD34) (Becton Dickinson, Mountain View, CA, USA); OKT11 (CD2) and OKIa1 (HLA-DR) (Ortho, Raritan, NJ, USA); J5 (CD10) and My9 (CD33) (Coulter, Hialeah, FL, USA); Tp40 (CD7) (kindly provided by Dr R Ueda, Nagoya City University, Japan); and MCS2 (CD13) (kindly provided by Dr E Tatsumi, Kobe University, Japan). Fluorescein isothiocyanateconjugated goat anti-mouse IgG F(ab) 2 fraction (GAM-FITC) (Coulter, Hialeah, FL, USA) was used as the secondary antibody. Cell samples were examined by flow cytometry using a Cytron (Ortho, Raritan, NJ, USA). We focused on the blast cell fraction of the cytogram to further characterize the phenotype of the leukemic cells. At least 5000 cells were examined for each marker. As cell samples consisted of more than 90% neoplastic cells on the cytospin preparations, samples were considered positive for a mAb if more than 20% cells showed immunofluorescence above control. Whole mouse Igs, IgG1 and IgG2 (Chemicon, Temecula, CA, USA) were used as the controls. The cytokine receptors evaluated were the a-chains of IL-2R, IL-3R, IL-4R, IL-5R, IL-7R and GM-CSFR, respectively; the b-chain of IL-2R; the common b-chain (bc) of IL-3R, IL-5R and GM-CSFR; IL-6R; the signal transducing receptor for IL-6 (gp130); the common g-chain (gc) of IL-2R, IL-4R and IL-7R; G-CSFR; c-fms (macrophage colony-stimulating factor receptor); c-mpl (thrombopoietin receptor); c-kit (stem cell factor receptor); and FLT3 (fms-like tyrosine kinase). MAbs used for the receptors were N3A 8 (IL-3Ra) and 5A5 9 (bc) (kindly provided by Dr T Kitamura, Tokyo University, Japan); anti-GM-CSFRa, IL-4Ra, IL-7Ra and c-mpl (Genzyme, Cambridge, MA, USA); anti-c-kit, IL-6R and gp130 (Serotec, Oxford, UK); anti-IL-5Ra, G-CSFR and gc (Pharmingen, San Diego, CA, USA); rat anti-fms (Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-Tac 10 (IL-2Ra) (kindly provided by Dr T Uchiyama, Kyoto University, Japan); Mikb1 11 (IL-2Rb) (kindly provided by Dr M Tsudo, Osaka Red Cross Hospital, Japan). In order to detect cytokine receptors, the determination was performed using the mean fluorescence intensity (MFI). The antibody binding capacity (sites/cell) was calculated using the MFI of test sample and the control on the basis of a calibration curve obtained from DAKO QIFIKIT and TallyCAL software (DAKO, Grostrip, Denmark), as described previously. 12 Whole mouse Igs, IgG1 and IgG2 (Chemicon, Temecula, CA, USA) were also used as the controls. Samples with o200 binding sites/cell calculated by the MFI on the basis of the calibration curve were judged as undetectable in this study.
Karyotype analysis
Karyotype analysis was performed on BM cells, as described previously. 13 The chromosomes were classified according to the International System for Human Cytogenetic Nomenclature (ISCN) (1985) .
Clinical outcome
All clinical data were reviewed retrospectively. One hundred and eighty-five patients were treated with Japanese ALL protocols including a combination of intravenous anthracycline (doxorubicin (DXR), mitoxantrone (MIT) or daunorubicin (DNR)), vincristine (VCR), cyclophosphamide (CY) and lasparaginase (Asp) and oral prednisolone (PSL), together with intrathecal methotrexate (MTX), cytarabine (Ara-C) and PSL: JCOG8702 14 CY for 1-3 days intermittently; 3000-6000 IU/m 2 Asp for 2-10 days. For patients who achieved a complete remission (CR), consolidation, intensification and maintenance chemotherapies were carried out as a post-remission therapy with additional drugs such as MTX, Ara-C, etoposide, behnoyl-ara-C, vindesine, DNR, aclarubicin and 6-mercaptopurine. Chemotherapeutic effects were evaluated in 179 of those patients and the remaining six patients were excluded because of early death within 2 weeks. CR was defined as the presence of less than 5% leukemia cells in BM aspirate after induction chemotherapy.
Statistical analysis
Correlations between the two groups were evaluated by w 2 analysis and the Mann-Whitney U-test. Analysis of the distribution between two continuous variables was performed by using the Spearman rank correlation test. Patient survival data were calculated by the Kaplan-Meyer method, and the difference was evaluated by generalized Wilcoxon's test. Univariate and multivariate analyses for EFS were performed with the Cox proportional hazard regression model. EFS was measured from the first day of therapy to relapse or death, and the EFS of patients who did not achieve CR was set at zero. The observation time was censored at the date of HSCT or at the last follow-up date if no event was noted. EFS was evaluated in 176 patients whose clinical course could be followed. Data were analyzed by STATISTICA software (StatSoft, Tulsa, OK, USA).
Results

Prevalence of cytokine receptor expression in ALL
The quantitative expression of IL-3Ra, GM-CSFRa, IL-5Ra, bc, IL-2Ra, IL-2Rb, IL-4Ra, IL-7Ra, gc, IL-6R, gp130, G-CSFR, c-fms, c-mpl, c-kit and FLT3 on cells from patients with ALL are shown in Table 1 . All cytokine receptors were expressed on ALL cells with a varying range of sites/cell. The levels of IL-5Ra, bc, IL-4Ra and G-CSFR were less than 1000 sites/cell. However, the levels of IL-3Ra, IL-2Ra, IL-2Rb, IL-7Ra, gc, c-mpl, c-kit and FLT3 exhibited a wide spectrum with more than 2000 sites/cell. One peculiar finding was that a wide distribution of IL-2Ra levels was unequalled and several cases exhibited extremely higher levels, more than 20 000 sites/cell, with a maximum level of 25 544 sites/cell.
Cytokine receptor expression and clinical outcome in ALL
We correlated clinical outcome, including CR rate and EFS, with cytokine receptor expression; which ranged widely over 2000 sites/cell and the mean levels more than 200 sites/cell. CR rate and EFS for each group of cytokine receptors are shown in Table 2 . For analysis of significance, we divided each group into high expressers and low expressers based upon the median levels of sites/cell. Cases expressing cytokine receptors at levels below the median are classified as low expressers and cases above the median are considered high expressers. There were no statistically significant differences in CR rate and EFS between high and low expressers of IL-3Ra, IL-7Ra, gc, c-kit and FLT3. However, IL-2Ra significantly correlated with a shorter EFS (P ¼ 0.00030) in the high expressers compared with the low expressers. Even in separate analyses for the B-lineage ALL cases (Table 3) , high IL-2Ra expressers showed a lower CR rate (P ¼ 0.0039) and a poorer EFS (P ¼ 0.00034) than low expressers. The extent of the level of high IL-2Ra expressers was extremely wide from 55 to 25 544 sites/cell. In order to confirm the relationship between the expression levels and EFS more clearly, we divided the levels into three categories such as IL2Ra o200; IL-2Ra X200 but o2000; and IL-2Ra X2000, and compared EFS among these groups. Figure 1 demonstrates that the EFS curve became worse as the level of IL-2Ra increased; EFS of the IL-2Ra X200 but o2000 group was inferior to that of the IL-2Ra o200 group (P ¼ 0.091) and IL-2Ra X2000 group considerably inferior to that of the IL-2Ra o200 group (P ¼ 0.0042).
Relationship between cytokine receptor expression and clinical and cellular features in ALL
We analyzed the relationship between cytokine receptor expression and clinical (age, gender and white blood cell (WBC) count at diagnosis) and cellular (B/T lineage, CD13/33, CD34 and Ph) features in patients with ALL ( Table 4) . As regards to the clinical features, elevated FLT3 levels correlated with patient age X60 years. C-kit was preferentially expressed in male than in female. IL-2Ra levels were elevated in cases with WBC counts X3 Â 10 4 /ml compared with cases with WBC o3 Â 10 4 /ml. Regarding the cellular features, IL-3Ra, IL-2Ra and FLT3 were highly expressed in B-lineage ALL cases, Abbreviations: ALL, acute lymphoblastic leukemia; CR, complete remission; EFS, event-free survival. Abbreviations: ALL, acute lymphoblastic leukemia; CR, complete remission; EFS, event-free survival.
Interleukin-2 receptor a-chain in ALL K Nakase et al whereas IL-7Ra, gc and c-kit predominated in T-lineage ALL cases. CD13/33 expression, which is a myeloid-lineage phenotype, was closely associated with higher levels of IL-3Ra, IL-2Ra, c-kit and FLT3. Stem cell antigen, CD34 exhibited a significant correlation to increased levels of IL-3Ra and IL-2Ra, and to decreased levels of IL-7Ra and gc. The karyotypic abnormality, Ph was closely related to higher levels of IL-2Ra and to lower levels of IL-7Ra and gc. IL-2Ra levels were about 10 times higher in Ph þ cases compared with Ph À cases. As the coexpression of CD13/33, CD34 and Ph is observed in a significant proportion of common ALL cases, we examined whether ALL cases expressing high IL-2Ra levels X2000 were associated to this type of ALL. Understandably, of the 19 such cases, 18 were common ALLs and one was T-lineage ALL.
IL-2Ra expression and other indicators of poor prognosis in B-lineage ALL
As only IL-2Ra expression showed a prognostic value, we evaluated the relationship between its expression and other indicators of poor prognosis in B-lineage ALL cases. The expression level of IL-2Ra (sites/cell) closely correlated with the percent of IL-2Ra þ cells (r ¼ 0.7888; Po0.0001) (Figure 2 ). In this analysis, in order to use IL-2Ra as a practical variable, we adopted IL-2Ra positivity, defined as more than 20% cells with immunofluorescence above control, which is the same as CD13/33 and CD34 positivity. Univariate analysis showed that factors indicating a poor prognosis for EFS were CD13/33 (P ¼ 0.0014), CD34 (P ¼ 0.0032), Ph (P ¼ 0.00011) and IL-2Ra (P ¼ 0.000020) ( Table 5 ). On the other hand, multivariate Figure 1 EFS for patients with ALL according to the IL-2Ra level (sites/ cell). EFS curve became worse as the level of IL-2Ra increased; EFS of the IL-2Ra X200 but o2000 group was inferior to that of the IL-2Ra o200 group (P ¼ 0.091) and that of the IL-2RaX2000 group considerably inferior to that of the IL-2Ra o200 group (P ¼ 0.0042).
Table 4
Correlation of cytokine receptor level with clinical and cellular features in patients with ALL Interleukin
and IL-2Ra (P ¼ 0.028) were independent adverse factors ( Table 5) . Intriguingly, as far as Ph þ ALL was concerned, the CR rate was lower (42.1 vs 83.3%, P ¼ 0.0049) ( Table 6 ) and EFS was worse (P ¼ 0.0057) (Figure 3 ) in the IL-2Ra þ cases than in the IL-2Ra À cases, respectively. Among Ph À ALL, EFS also tended to be poorer in the IL-2Ra þ cases compared with the IL-2Ra À cases (P ¼ 0.077) (Figure 3 ).
Discussion
A variety of cytokine/cytokine receptor systems have been shown to affect the biological behavior of leukemia cells. 4, 5 However, there have been few reports 6, 7 regarding the prevalence and clinical significance of cytokine receptor expression on cells from ALL. In the present study, we demonstrated that all the receptors we evaluated (IL-3Ra, GMCSFRa, IL-5Ra, bc, IL-2Ra, IL-2Rb, IL-4Ra, IL-7Ra, gc, IL-6R, gp130, G-CSFR, c-fms, c-mpl, c-kit and FLT3) were expressed with a variable range of levels on ALL cells. Among them, IL3Ra, IL-2Ra, IL-7Ra, gc, c-kit and FLT3 had statistically significant correlations with at least one clinical or cellular features of ALL. The major finding of this study was that ALL cases with elevated IL-2Ra levels exhibited a shorter EFS than those with low IL-2Ra levels. This tendency was also identified in the separate analysis for B-lineage ALL cases. There were no other receptors that revealed a clinical relevance similar to IL2Ra expression. As previously described, 19, 20 cellular characteristics of ALL cases with increased IL-2Ra levels would appear to indicate that such leukemias concentrate in common ALL because high levels of this receptor were closely associated with the expression of the B-lineage, CD13/33, CD34 and the presence of Ph. Indeed, most of the cases expressing high IL-2Ra belonged to this type of leukemia. Of interest is that Ph þ cases displayed extremely increased this receptor levels. Paietta et al. 21 described that IL-2Ra expression may serve as a surrogate marker for the presence of BCR/ABL fusion genes (Ph resultant genes). On the other hand, multivariate analysis for EFS in B-lineage ALL cases demonstrated that both Ph and IL2Ra as independent adverse factors. Among Ph þ ALL, both CR rate and EFS were worse in the IL-2Ra þ cases than in the IL2Ra À cases, suggesting that IL-2Ra expression confers a greater prognostic impact on Ph þ ALL. Even in Ph À ALL, the IL-2Ra þ cases tended to exhibit a poorer EFS compared with the IL-2Ra À cases. An unequalled broad range of IL-2Ra levels allows us to speculate other roles different from one of the growth factor receptors. Actually, cells from several IL-2Ra þ precursor-B ALL cases showed no IL-2 responsiveness (DNA synthesis) irrespective of IL-2Rb and/or gc expression (data not shown), which was also shown by several studies. 20, 22 Ourselves 19, 23 and other investigators 24 previously demonstrated a marked increase of serum-soluble IL-2R (sIL-2R) in IL-2Ra þ leukemia. As sIL-2R competes with IL-2R on normal lymphocytes for the ligand, 25 IL2Ra on the cell surface of leukemia cells coupled to the increased sIL-2R could enhance leukemia progression by suppressing host antitumor immunity, [26] [27] [28] and this may be one possible explanation for the leukocytosis (leukemic cell proliferation) and the dismal clinical course of IL-2Ra þ ALL. Regarding the other receptors, cases with elevated IL-3Ra levels showed a similar trend of cellular characteristics (expression of the B-lineage, CD13/33 and CD34) as those with higher IL-2Ra levels. Although such cases in AML were reported to have a poor prognosis, 29 our study demonstrated no prognostic impact on ALL cases. IL-7Ra and gc correlated with the expression of the T lineage, and with the negativity of CD34 and Ph, suggesting their preferential expression in slightly mature T-lineage ALL cells. c-kit expression, though not so high, exhibited a male predominance like certain non-hematological malignancies. 30 We previously described a close correlation between c-kit gene expression and CD13 positivity of T-ALL cells. 31 In this study, we showed that cell surface c-kit levels were also associated with the expression of CD13/33. FLT3 is reportedly expressed in a high proportion of AML and Blineage ALL, but not in T-lineage ALL. 32, 33 We demonstrated that higher FLT3 levels closely correlated with patient age X60 years, and with the expression of the B-lineage and CD13/33. FLT3 mutations have been reported to associate with a poor prognosis in AML. 34, 35 However, as little data are available about the relationship between surface FLT3 levels and its Interleukin-2 receptor a-chain in ALL K Nakase et al genetic aberration, 36 further studies are needed to clarify FLT3 involvement in ALL as well as AML.
In conclusion, several cytokine receptors were associated with certain cellular and clinical features, but only IL-2Ra had a prognostic value and should be considered as a major prognostic factor for adult ALL that is comparable with Ph. As therapeutic strategies, at present, the accepted curative treatment of Ph þ ALL is almost limited to allogeneic HSCT, 2, 3 although imatinib is a promising agent for these leukemias. 37 Similarly, we believe that IL-2Ra þ ALL also requires treatments other than conventional chemotherapy to improve the prognosis. Waldmann et al. 38, 39 reported an immunotherapy using IL-2Ra-directed mAb and its efficacy for IL-2Ra expressing leukemia/lymphoma. Accordingly, IL-2Ra þ ALL may be one candidate for such therapy.
